Home > Insider Trading > Filing (0000914190-16-000516)

Filing Details

Accession Number:: 0000914190-16-000516
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-01-14 17:19:25
Reporting Period:: 2016-01-12

Filing Date:: 2016-01-14
Accepted Time:: 2016-01-14 17:19:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1195116	Arno Therapeutics Inc	ARNI	Pharmaceutical Preparations (2834)	522286452

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1568077	Tomer Kariv	200 Route 31 North Suite 104 Flemington NJ 08822		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-01-12	707,868	$0.35	1,347,327	No	4	P	Indirect	By Pontifax (Cayman) II L.P.
Common Stock	Acquisiton	2016-01-12	533,208	$0.35	1,014,888	No	4	P	Indirect	By Pontifax (Israel) II L.P.
Common Stock	Acquisiton	2016-01-12	206,986	$0.35	393,968	No	4	P	Indirect	By Pontifax (Israel) II - Individual Investors L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Pontifax (Cayman) II L.P.
No	4	P	Indirect	By Pontifax (Israel) II L.P.
No	4	P	Indirect	By Pontifax (Israel) II - Individual Investors L.P.

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (right to buy)	$8.00		2020-11-05	3,750	3,750	Direct
Common Stock	Stock Option (right to buy)	$2.40		2023-11-04	68,448	68,448	Direct
Common Stock	Stock Option (right to buy)	$2.90		2024-01-24	34,224	34,224	Direct
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-12-18	2017-12-18	599,064	599,064	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	380,714	380,714	Indirect
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-12-18	2017-12-18	451,252	451,252	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	286,777	286,777	Indirect
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-12-18	2017-12-18	175,170	175,170	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	111,323	111,323	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2020-11-05	3,750	3,750	Direct
2023-11-04	68,448	68,448	Direct
2024-01-24	34,224	34,224	Direct
2017-12-18	599,064	599,064	Indirect
2018-10-29	380,714	380,714	Indirect
2017-12-18	451,252	451,252	Indirect
2018-10-29	286,777	286,777	Indirect
2017-12-18	175,170	175,170	Indirect
2018-10-29	111,323	111,323	Indirect

Footnotes

On January 12, 2016, Pontifax (Cayman) II L.P. was issued 707,868 shares upon the automatic conversion of $247,753.81 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to Pontifax (Cayman) II L.P. by the Issuer on October 21, 2015.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
On January 12, 2016, Pontifax (Israel) II L.P. was issued 533,208 shares upon the automatic conversion of $186,622.98 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to Pontifax (Israel) II L.P. by the Issuer on October 21, 2015.
On January 12, 2016, Pontifax (Israel) II - Individual Investors L.P. was issued 206,986 shares upon the automatic conversion of $72,445.12 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to Pontifax (Israel) II - Individual Investors L.P. by the Issuer on October 21, 2015.
Currently exercisable.
Vests in equal 36-monthly installments commencing 12/4/13.
Vests in equal 12-monthly installments commencing 2/24/14.
As a result of the Issuer's 1/12/16 private placement of common stock at $0.35/share, the exercise price and number of shares subject to the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.